Rx Product News

Published Online: Monday, June 16, 2014

Marketed by
: kaléo, Inc
Indication: The FDA has approved Evzio (naloxone hydrochloride injection) for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Evzio is for intramuscular or subcutaneous use only. It should be administered to adult or pediatric patients in the anterolateral aspect of the thigh, through clothing if necessary. Emergency medical care should be sought immediately after use. Additional doses may be administered every 2 to 3 minutes until emergency medical assistance arrives.
Dosage Form: Prefilled autoinjector: 0.4 mg/0.4 mL naloxone hydrochloride solution
For More Information: www.evzio.com

Marketed by:
Bayer HealthCare Pharmaceuticals Inc
Indication: Through its service Rosacea Concierge: Your Partner in Rosacea Care, Bayer HealthCare provides 24-hour telephone access to nurses who specialize in rosacea education. This service is designed to assist patients with rosacea, especially those who have received a recent diagnosis. Rosacea Concierge also offers a coupon for Finacea (azelaic acid) gel, 15%, which is indicated for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Finacea should be applied to the affected area(s) in a thin layer twice daily.
Dosage Form: Gel: 15%
For More Information: http://rosacea-support.org/rosacea-concierge-from-bayer-healthcare.html; www.myfinacea.com/index.php

Marketed by:
Bristol-Myers Squibb Company; AstraZeneca Pharmaceuticals LP
Indication: Farxiga, a sodium-glucose cotransporter 2 inhibitor, has been FDA approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (DM). Farxiga is not for treatment of type 1 DM or diabetic ketoacidosis. The recommended starting dose is 5 mg once daily, taken in the morning, with or without food. Renal function should be assessed before initiating Farxiga.
Dosage Form: Tablets: 5 and 10 mg
For More Information: www.farxiga-hcp.com

Marketed by:
Bristol-Myers Squibb Company; Pfizer Inc
Indication: The FDA has approved Eliquis (apixaban), a factor Xa inhibitor anticoagulant, to reduce the risk of blood clots following hip or knee replacement surgery. Eliquis is also indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. For prophylaxis of deep vein thrombosis, the recommended dose of Eliquis is 2.5 mg orally twice daily.
Dosage Form: Tablets: 2.5 and 5 mg
For More Information: www.eliquis.com

Latest Articles
As today is World AIDS Day, pharmacists across the globe may be renewing their interest in quashing HIV infection and providing support for infected patients.
Pharmacists are in a great position to impart valuable heart-related wisdom to their patients.
Shifts in sleep schedules may increase an individual’s risk for diabetes.
Qualgen has taken corrective actions concerning its compounding facility conditions and sterility processes.
Latest Issues